MedTrace Logo

Repetitive GON Blockade for Menstrual Migraine

NCT07576309 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-05-08

No results posted yet for this study

Summary

: The primary objective of this prospective, randomized, double-blind, placebo-controlled clinical trial is to evaluate whether repetitive bilateral greater occipital nerve (GON) blockade administered with a local anesthetic (0.5% bupivacaine) significantly reduces headache severity, attack duration, and the number of pain days in female patients with menstrual migraine compared to a placebo group (normal saline). Patients will receive injections twice a month for three months (seven days before the expected onset of menstruation and on the first day of menstruation).

Conditions

  • Menstrual Migraine
  • Menstrually Related Migraine

Interventions

DRUG

0.5% bupivacaine

Bilateral greater occipital nerve (GON) blockade using a local anesthetic.

OTHER

Normal Saline

Bilateral greater occipital nerve (GON) blockade using placebo (normal saline).

Sponsors & Collaborators

  • Saglik Bilimleri Universitesi

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-19
Primary Completion
2025-05-30
Completion
2025-11-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07576309 on ClinicalTrials.gov